Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8948815 | 0.86 | CHRNB2 (0.50) | HTR2CALDH1A1MAPK1L3MBTL1GLA | |
| SCHEMBL3922320 | 0.85 | NMT1 (0.50) | HTR2CALDH1A1MAPK1L3MBTL1GLA | |
| SCHEMBL15369724 | 0.83 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1GLASLC6A2 | |
| SCHEMBL20859045 | 0.82 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1GLASLC6A2 | |
| SCHEMBL20859042 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1GLASLC6A2 | |
| SCHEMBL20859044 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1GLASLC6A2 | |
| SCHEMBL581885 | 0.78 | CTSL (0.51) | HTR2CSLC6A2SLC6A3 | |
| SCHEMBL17726560 | 0.78 | HTR2C (0.55) | HTR2CALDH1A1MAPK1L3MBTL1GLA | |
| SCHEMBL23705529 | 0.77 | LMNA (0.65) | HTR2CALDH1A1L3MBTL1KMT2ALMNA | |
| SCHEMBL20859110 | 0.77 | ALDH1A1 (0.46) | ALDH1A1MAPK1L3MBTL1GLASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | ACTION MEDICAL TECHNOLOGIES, LLC | 2018-11-08 | — | — | US | disclosed |
| US-10053468-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
| EP-3018126-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-5532255-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053468-B2 | Heterocyclic compound | RORC, RORB, RORA | HTR2C 2254/4885ALDH1A1 210/4885MAPK1 1201/4885 |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | HTR2C 2254/4885ALDH1A1 210/4885MAPK1 1201/4885 |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | HTR2C 2254/4885ALDH1A1 210/4885MAPK1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.